Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Research & Development (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Research & Development for 11 consecutive years, with $88.7 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 24.15% to $88.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $388.9 million through Dec 2025, down 16.61% year-over-year, with the annual reading at $388.9 million for FY2025, 16.61% down from the prior year.
  • Research & Development for Q4 2025 was $88.7 million at Intellia Therapeutics, down from $94.7 million in the prior quarter.
  • The five-year high for Research & Development was $133.1 million in Q1 2022, with the low at $39.3 million in Q1 2021.
  • Average Research & Development over 5 years is $97.0 million, with a median of $98.6 million recorded in 2022.
  • The sharpest move saw Research & Development surged 238.87% in 2022, then dropped 27.03% in 2023.
  • Over 5 years, Research & Development stood at $71.2 million in 2021, then skyrocketed by 40.57% to $100.0 million in 2022, then rose by 8.94% to $109.0 million in 2023, then increased by 7.25% to $116.9 million in 2024, then dropped by 24.15% to $88.7 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $88.7 million, $94.7 million, and $97.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.